 Breelyn Wilky
Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 20 | 2025 | 176 | 7.230 |
Why?
| | Soft Tissue Neoplasms | 9 | 2024 | 112 | 3.090 |
Why?
| | Gastrointestinal Stromal Tumors | 5 | 2024 | 46 | 1.960 |
Why?
| | Immunotherapy | 10 | 2023 | 592 | 1.710 |
Why?
| | Fibromatosis, Aggressive | 3 | 2022 | 17 | 1.660 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2023 | 7 | 1.470 |
Why?
| | Molecular Targeted Therapy | 6 | 2019 | 390 | 1.450 |
Why?
| | Bone Neoplasms | 8 | 2025 | 231 | 1.400 |
Why?
| | Hemangiosarcoma | 2 | 2021 | 20 | 1.310 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1565 | 1.160 |
Why?
| | Precision Medicine | 3 | 2024 | 387 | 1.110 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 964 | 1.040 |
Why?
| | Biomarkers, Tumor | 8 | 2022 | 1181 | 1.000 |
Why?
| | Antineoplastic Agents | 8 | 2023 | 2061 | 0.990 |
Why?
| | Circulating Tumor DNA | 2 | 2022 | 28 | 0.810 |
Why?
| | Leiomyosarcoma | 1 | 2022 | 27 | 0.790 |
Why?
| | Pyrimidines | 2 | 2018 | 459 | 0.780 |
Why?
| | Sulfonamides | 2 | 2018 | 496 | 0.770 |
Why?
| | Sarcoma, Ewing | 2 | 2025 | 89 | 0.660 |
Why?
| | Immunomodulation | 2 | 2019 | 93 | 0.630 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2019 | 181 | 0.600 |
Why?
| | Salvage Therapy | 1 | 2019 | 134 | 0.590 |
Why?
| | Neoplasms | 5 | 2024 | 2470 | 0.550 |
Why?
| | Humans | 57 | 2025 | 129652 | 0.530 |
Why?
| | Medical Oncology | 3 | 2025 | 272 | 0.520 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2025 | 759 | 0.500 |
Why?
| | DEAD-box RNA Helicases | 1 | 2015 | 66 | 0.470 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 297 | 0.470 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 97 | 0.460 |
Why?
| | Chondrosarcoma | 3 | 2023 | 15 | 0.460 |
Why?
| | Solitary Fibrous Tumors | 1 | 2013 | 3 | 0.430 |
Why?
| | Thoracic Neoplasms | 1 | 2013 | 35 | 0.420 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 2 | 2024 | 4 | 0.420 |
Why?
| | Prognosis | 7 | 2022 | 3794 | 0.410 |
Why?
| | Liposarcoma | 2 | 2023 | 27 | 0.400 |
Why?
| | Combined Modality Therapy | 6 | 2025 | 1206 | 0.390 |
Why?
| | Sarcoma, Synovial | 2 | 2024 | 17 | 0.390 |
Why?
| | Giant Cell Tumor of Bone | 2 | 2021 | 6 | 0.360 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3408 | 0.350 |
Why?
| | Bone Density Conservation Agents | 2 | 2021 | 70 | 0.340 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1171 | 0.340 |
Why?
| | Antigens, Neoplasm | 2 | 2024 | 309 | 0.330 |
Why?
| | Adult | 19 | 2025 | 35577 | 0.300 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 891 | 0.290 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 45 | 0.290 |
Why?
| | Treatment Outcome | 10 | 2024 | 10230 | 0.280 |
Why?
| | Male | 18 | 2025 | 63682 | 0.250 |
Why?
| | Indazoles | 2 | 2018 | 65 | 0.240 |
Why?
| | Middle Aged | 14 | 2025 | 31155 | 0.240 |
Why?
| | Liquid Biopsy | 2 | 2022 | 9 | 0.240 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2015 | 52 | 0.230 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 15 | 0.230 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 15 | 0.230 |
Why?
| | Hemangioendothelioma, Epithelioid | 1 | 2024 | 6 | 0.230 |
Why?
| | Oncologists | 1 | 2025 | 35 | 0.230 |
Why?
| | Denosumab | 2 | 2021 | 8 | 0.230 |
Why?
| | Osteosarcoma | 1 | 2025 | 72 | 0.230 |
Why?
| | Imidazoles | 2 | 2015 | 234 | 0.230 |
Why?
| | Mutation | 5 | 2025 | 3717 | 0.220 |
Why?
| | Liposarcoma, Myxoid | 1 | 2024 | 9 | 0.220 |
Why?
| | Sodium Tetradecyl Sulfate | 1 | 2024 | 2 | 0.220 |
Why?
| | Electroporation | 1 | 2024 | 37 | 0.220 |
Why?
| | Imatinib Mesylate | 1 | 2024 | 76 | 0.220 |
Why?
| | Female | 18 | 2025 | 68777 | 0.220 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2023 | 29 | 0.210 |
Why?
| | Aged | 11 | 2025 | 22104 | 0.210 |
Why?
| | Cancer Vaccines | 3 | 2019 | 164 | 0.210 |
Why?
| | Young Adult | 9 | 2025 | 12427 | 0.210 |
Why?
| | Tetrahydronaphthalenes | 1 | 2023 | 30 | 0.210 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2025 | 232 | 0.200 |
Why?
| | Job Satisfaction | 1 | 2025 | 203 | 0.200 |
Why?
| | Anemia | 1 | 2024 | 160 | 0.200 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 610 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 106 | 0.190 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2019 | 220 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2024 | 186 | 0.190 |
Why?
| | Survival Rate | 2 | 2019 | 1877 | 0.190 |
Why?
| | Postoperative Complications | 1 | 2013 | 2483 | 0.190 |
Why?
| | Academic Medical Centers | 1 | 2025 | 481 | 0.190 |
Why?
| | Translocation, Genetic | 2 | 2019 | 97 | 0.190 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 17 | 0.190 |
Why?
| | Quinazolines | 1 | 2023 | 244 | 0.190 |
Why?
| | Clinical Trials, Phase II as Topic | 3 | 2019 | 72 | 0.180 |
Why?
| | Tumor Microenvironment | 3 | 2019 | 634 | 0.180 |
Why?
| | beta Catenin | 1 | 2022 | 223 | 0.170 |
Why?
| | Retrospective Studies | 6 | 2024 | 14518 | 0.170 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2019 | 15 | 0.170 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2019 | 21 | 0.170 |
Why?
| | Osteoblasts | 1 | 2021 | 124 | 0.170 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2019 | 23 | 0.170 |
Why?
| | Neoplasm Staging | 4 | 2018 | 1295 | 0.170 |
Why?
| | Gene Fusion | 1 | 2019 | 24 | 0.160 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 210 | 0.160 |
Why?
| | Oncogene Fusion | 1 | 2019 | 14 | 0.160 |
Why?
| | Animals | 10 | 2024 | 35361 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 84 | 0.160 |
Why?
| | Tumor Escape | 1 | 2019 | 39 | 0.160 |
Why?
| | Gene Amplification | 1 | 2019 | 105 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2024 | 640 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 487 | 0.160 |
Why?
| | Cell Line, Tumor | 5 | 2024 | 3215 | 0.160 |
Why?
| | Transcriptome | 1 | 2025 | 887 | 0.150 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 7 | 0.150 |
Why?
| | Neurofibrosarcoma | 1 | 2018 | 7 | 0.150 |
Why?
| | Carcinogenesis | 1 | 2019 | 213 | 0.140 |
Why?
| | T-Lymphocytes | 3 | 2024 | 1928 | 0.140 |
Why?
| | Hematology | 1 | 2017 | 14 | 0.140 |
Why?
| | Melanoma | 1 | 2024 | 730 | 0.140 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2019 | 231 | 0.140 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4897 | 0.140 |
Why?
| | Actins | 1 | 2019 | 411 | 0.140 |
Why?
| | Radiography | 2 | 2021 | 798 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 769 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 412 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 752 | 0.130 |
Why?
| | Rhabdoid Tumor | 1 | 2018 | 98 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1004 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 295 | 0.130 |
Why?
| | Simulation Training | 1 | 2017 | 82 | 0.130 |
Why?
| | Drug Discovery | 1 | 2017 | 131 | 0.120 |
Why?
| | Glutarates | 1 | 2015 | 8 | 0.120 |
Why?
| | Benzeneacetamides | 1 | 2015 | 7 | 0.120 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7086 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 589 | 0.120 |
Why?
| | Azepines | 1 | 2015 | 89 | 0.120 |
Why?
| | Drug Monitoring | 1 | 2016 | 216 | 0.120 |
Why?
| | Receptor, IGF Type 1 | 1 | 2014 | 65 | 0.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 211 | 0.110 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 315 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 1 | 2024 | 2535 | 0.110 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2014 | 71 | 0.110 |
Why?
| | Ovarian Neoplasms | 1 | 2019 | 490 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 273 | 0.110 |
Why?
| | Paired Box Transcription Factors | 1 | 2014 | 40 | 0.110 |
Why?
| | Apoptosis | 3 | 2023 | 2503 | 0.110 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 396 | 0.110 |
Why?
| | Chordoma | 1 | 2013 | 16 | 0.110 |
Why?
| | Macrophages | 1 | 2021 | 1480 | 0.110 |
Why?
| | Benzimidazoles | 1 | 2014 | 162 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 339 | 0.110 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2013 | 93 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2019 | 1119 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1367 | 0.100 |
Why?
| | Rhabdomyosarcoma | 1 | 2014 | 64 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 759 | 0.100 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2013 | 195 | 0.100 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 185 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2282 | 0.100 |
Why?
| | Disease-Free Survival | 1 | 2014 | 648 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2015 | 814 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1356 | 0.100 |
Why?
| | HLA-A Antigens | 2 | 2024 | 53 | 0.100 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 201 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 827 | 0.100 |
Why?
| | Connective Tissue | 2 | 2022 | 38 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 220 | 0.090 |
Why?
| | Doxorubicin | 1 | 2013 | 325 | 0.090 |
Why?
| | Sirolimus | 1 | 2013 | 266 | 0.090 |
Why?
| | Curriculum | 1 | 2017 | 917 | 0.090 |
Why?
| | Mice | 5 | 2024 | 16937 | 0.090 |
Why?
| | Immunohistochemistry | 3 | 2021 | 1698 | 0.080 |
Why?
| | NF-kappa B | 1 | 2013 | 653 | 0.080 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2019 | 50 | 0.080 |
Why?
| | Consensus | 2 | 2022 | 616 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1368 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2018 | 285 | 0.070 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2024 | 9 | 0.060 |
Why?
| | Chromones | 1 | 2024 | 45 | 0.060 |
Why?
| | Adolescent | 4 | 2021 | 20394 | 0.060 |
Why?
| | Career Mobility | 1 | 2025 | 68 | 0.060 |
Why?
| | Ifosfamide | 1 | 2024 | 34 | 0.060 |
Why?
| | Microsatellite Instability | 1 | 2024 | 37 | 0.060 |
Why?
| | Anilides | 1 | 2024 | 73 | 0.060 |
Why?
| | Cohort Studies | 1 | 2014 | 5420 | 0.060 |
Why?
| | DNA Copy Number Variations | 1 | 2025 | 170 | 0.060 |
Why?
| | Morpholines | 1 | 2024 | 122 | 0.050 |
Why?
| | Frameshift Mutation | 1 | 2023 | 32 | 0.050 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 20 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 42 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1706 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2024 | 164 | 0.050 |
Why?
| | Quinolines | 1 | 2024 | 156 | 0.050 |
Why?
| | Workload | 1 | 2025 | 153 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2023 | 64 | 0.050 |
Why?
| | Disease Progression | 2 | 2022 | 2635 | 0.050 |
Why?
| | Valine | 1 | 2023 | 81 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 148 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2021 | 1902 | 0.050 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2023 | 80 | 0.050 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2023 | 132 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 427 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 110 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 121 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2024 | 424 | 0.050 |
Why?
| | Cytokines | 2 | 2019 | 2017 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 716 | 0.040 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2019 | 51 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 7133 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 683 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 596 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 511 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 521 | 0.040 |
Why?
| | Cell Lineage | 1 | 2021 | 333 | 0.040 |
Why?
| | Oncolytic Viruses | 1 | 2018 | 7 | 0.040 |
Why?
| | Oncolytic Virotherapy | 1 | 2018 | 13 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2018 | 32 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1876 | 0.040 |
Why?
| | Margins of Excision | 1 | 2018 | 38 | 0.040 |
Why?
| | SMARCB1 Protein | 1 | 2018 | 29 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2024 | 2871 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 210 | 0.040 |
Why?
| | SEER Program | 1 | 2018 | 206 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 140 | 0.030 |
Why?
| | Syndrome | 1 | 2018 | 341 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1443 | 0.030 |
Why?
| | Pedigree | 1 | 2018 | 487 | 0.030 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2017 | 75 | 0.030 |
Why?
| | Models, Molecular | 1 | 2021 | 1492 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2021 | 2406 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 244 | 0.030 |
Why?
| | Immune System | 1 | 2017 | 175 | 0.030 |
Why?
| | Risk | 1 | 2018 | 854 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 704 | 0.030 |
Why?
| | Population Surveillance | 1 | 2018 | 439 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2644 | 0.030 |
Why?
| | PAX3 Transcription Factor | 1 | 2014 | 11 | 0.030 |
Why?
| | Forkhead Box Protein O1 | 1 | 2014 | 21 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2391 | 0.030 |
Why?
| | Radiation | 1 | 2014 | 24 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 317 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2014 | 95 | 0.030 |
Why?
| | Chondrocytes | 1 | 2015 | 203 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 192 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 438 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 875 | 0.030 |
Why?
| | Rats | 1 | 2021 | 5500 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1838 | 0.020 |
Why?
| | Communication | 1 | 2017 | 846 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3076 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2704 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4063 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1038 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 513 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1007 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1279 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3083 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1839 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 2012 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3973 | 0.020 |
Why?
| | United States | 1 | 2025 | 13903 | 0.020 |
Why?
| | Child | 2 | 2019 | 20883 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2073 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5406 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 10517 | 0.010 |
Why?
| | Infant | 1 | 2018 | 9024 | 0.010 |
Why?
|
|
Wilky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|